Stents are medical devices that treat various types of vascular diseases. The global market for stents has grown due to the increase in vascular diseases caused by complications of adult diseases such as hypertension and diabetes. Among them, the peripheral vascular stent market is a high value-added industry that is expected to continue to grow due to the increase in patients with peripheral arterial disease. This increase has been influenced by the aging population and increased treatment demand in emerging markets. The global market for peripheral vascular stents is expected to grow from $10,301 million in 2021 to $13,368 million in 2026 at an average annual growth rate of 5.3%. North America currently occupies the largest market share, but it is expected to grow significantly in the future, centering on the markets of the Asia-Pacific region. Demand for peripheral vascular stents is also growing in Korea as the number of patients with peripheral vascular disease and health insurance costs continuously increase. Accordingly, the importance of market entry by domestic companies with stent manufacturing technology is increasing. In this study, we confirmed the competitive situation based on the industrial structure and market analysis of the biodegradable drug-eluting stent. This technology has a lower risk of thrombosis and a lower possibility of reoperation than the previously commercialized metal-based peripheral vascular stent. Based on our analysis, we presented a commercialization strategy for domestic companies with stent manufacturing technology.